Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Bajaj, Jasmohan S ^a   Betrapally, Naga S ^a   Hylemon, Phillip B ^b   Thacker, Leroy R ^b   Daita, Kalyani ^a   Kang, Dae Joong ^a   White, Melanie B ^a   Unser, Ariel B ^a   Fagan, Andrew ^a   Gavis, Edith A ^a   Sikaroodi, Masoumeh ^a   Dalmet, Swati ^a   Heuman, Douglas M ^a   Gillevet, Patrick M ^a  

^a GEORGE MASON UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLICATION; DEMOGRAPHY; FECES; FEMALE; HOSPITALIZATION; HUMAN; INTESTINE FLORA; INTESTINE MUCOSA; LIVER CIRRHOSIS; MALE; MICROBIOLOGY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRINCIPAL COMPONENT ANALYSIS; STATISTICAL MODEL; TREATMENT OUTCOME;

DEMOGRAPHY; DIABETES MELLITUS, TYPE 2; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HOSPITALIZATION; HUMANS; INTESTINAL MUCOSA; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; TREATMENT OUTCOME;

EID: 84951859197     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18559     Document Type: Article

References (41)

1. Bajaj, J. S. et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology 56, 2328-2335 (2012).
2. Elkrief, L. et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology 60, 823-831, doi: 10.1002/hep.27228 (2014).
3. Wlazlo, N. et al. High prevalence of diabetes mellitus in patients with liver cirrhosis. Diabet Med 27, 1308-1311 (2010).
4. Zein, N. N., Abdulkarim, A. S., Wiesner, R. H., Egan, K. S. & Persing, D. H. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. Journal of hepatology 32, 209-217 (2000).
5. Volk, M. L., Tocco, R. S., Bazick, J., Rakoski, M. O. & Lok, A. S. Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol 107, 247-252, doi: 10.1038/ajg.2011.314 (2012).
6. Bajaj, J. S., Betrapally, N. S. & Gillevet, P. M. Decompensated cirrhosis and microbiome interpretation. Nature, doi: 10.1038/nature14851 (2015).
7. Shawcross, D. L. Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy? Expert review of gastroenterology & hepatology 9, 539-542, doi: 10.1586/17474124.2015.1035257 (2015).
8. Qin, N. et al. Alterations of the human gut microbiome in liver cirrhosis. Nature, doi: 10.1038/nature13568 (2014).
9. Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55-60, doi: 10.1038/nature11450 (2012).
10. Zhang, X. et al. Human gut microbiota changes reveal the progression of glucose intolerance. PloS one 8, e71108, doi: 10.1371/journal. pone.0071108 (2013).
11. Singal, A. G. et al. An automated model using electronic medical record data identifies patients with cirrhosis at high risk for readmission. Clin Gastroenterol Hepatol 11, 1335-1341 e1331, doi: 10.1016/j.cgh.2013.03.022 (2013).
12. Bajaj, J. S. et al. Systems Biology Analysis of Omeprazole Therapy in Cirrhosis Demonstrates Significant Shifts in Gut Microbiota Composition and Function. Am J Physiol Gastrointest Liver Physiol, doi: 10.1152/ajpgi.00268.2014 (2014).
13. Berman, K. et al. Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol 9, 254-259, doi: 10.1016/j.cgh.2010.10.035 (2011).
14. Bajaj, J. S. et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. Journal of hepatology 60, 940-947, doi: 10.1016/j.jhep.2013.12.019 (2014).
15. Chen, Y. et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 54, 562-572 (2011).
16. Chen, Y. et al. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. J Gastroenterol Hepatol, doi: 10.1111/jgh.12932 (2015).
17. Bajaj, J. S. et al. Salivary Microbiota Reflects Changes in Gut Microbiota in Cirrhosis with Hepatic Encephalopathy. Hepatology, doi: 10.1002/hep.27819 (2015).
18. Nava, G. M. & Stappenbeck, T. S. Diversity of the autochthonous colonic microbiota. Gut Microbes 2 (2011). doi: 10.4161/gmic.2.2.15416
19. Kakiyama, G. et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. Journal of hepatology 58, 949-955 (2013).
20. Stentz, R. et al. Cephalosporinases associated with outer membrane vesicles released by Bacteroides spp. protect gut pathogens and commensals against beta-lactam antibiotics. J Antimicrob Chemother 70, 701-709, doi: 10.1093/jac/dku466 (2015).
21. Manges, A. R. et al. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease. J Infect Dis 202, 1877-1884, doi: 10.1086/657319 (2010).
22. Rosa, H., Silverio, A. O., Perini, R. F. & Arruda, C. B. Bacterial infection in cirrhotic patients and its relationship with alcohol. Am J Gastroenterol 95, 1290-1293 (2000).
23. Human Microbiome Project, C. Structure, function and diversity of the healthy human microbiome. Nature 486, 207-214, doi: 10.1038/nature11234 (2012).
24. Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179-185, doi: 10.1038/nature10809 (2012).
25. Sharma, B. C., Sharma, P., Agrawal, A. & Sarin, S. K. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 137, 885-891, 891 e881, doi: 10.1053/j.gastro.2009.05.056 (2009).
26. Bajaj, J. S. et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PloS one 8, e60042, doi: 10.1371/journal.pone.0060042 (2013).
27. Bass, N. M. et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362, 1071-1081, doi: 10.1056/NEJMoa0907893 (2010).
28. Dhiman, R. K. et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 147, 1327-1337 e1323, doi: 10.1053/j.gastro.2014.08.031 (2014).
29. Festi, D. et al. Gut microbiota and metabolic syndrome. World J Gastroenterol 20, 16079-16094, doi: 10.3748/wjg.v20.i43.16079 (2014).
30. Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022-1023, doi: 10.1038/4441022a (2006).
31. Abu-Shanab, A. & Quigley, E. M. The role of the gut microbiota in nonalcoholic fatty liver disease. Nature reviews. Gastroenterology & hepatology 7, 691-701, doi: 10.1038/nrgastro.2010.172 (2010).
32. Malinchoc, M. et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31, 864-871, doi: 10.1053/he.2000.5852 (2000).
33. O'Leary, J. G. et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol 13, 753-759 e751-752, doi: 10.1016/j.cgh.2014.07.060 (2015).
34. Bajaj, J. S., Ratliff, S. M., Heuman, D. M. & Lapane, K. L. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther 36, 866-874, doi: 10.1111/apt.12045 (2012).
35. Melgar, S. & Nieuwdorp, M. Are Proton Pump Inhibitors Affecting Intestinal Microbiota Health? Gastroenterology, doi: 10.1053/j. gastro.2015.08.039 (2015).
36. Appenrodt, B. et al. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology 51, 1327-1333, doi: 10.1002/hep.23440 (2010).
37. Segata, N. et al. Metagenomic biomarker discovery and explanation. Genome Biol 12, R60, doi: 10.1186/gb-2011-12-6-r60 (2011).
38. Bajaj, J. S. et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 303, G675-685, doi: 10.1152/ajpgi.00152.2012 (2012).
39. Gillevet, P., Sikaroodi, M., Keshavarzian, A. & Mutlu, E. A. Quantitative assessment of the human gut microbiome using multitag pyrosequencing. Chem Biodivers 7, 1065-1075 (2010).
40. Hamady, M. & Knight, R. Microbial community profiling for human microbiome projects: Tools, techniques, and challenges. Genome Res 19, 1141-1152 (2009).
41. White, J. R., Nagarajan, N. & Pop, M. Statistical methods for detecting differentially abundant features in clinical metagenomic samples. PLoS Comput Biol 5, e1000352 (2009).